TG100-115 Patients are continuously with advanced phase CML

w During treatment with imatinib. These observations show that myelosuppression induced by imatinib further consequence of the therapeutic effect on the leuk Mix clone an inhibitory effect on h Hematopoietic is ESE normal. Details of the treatment of side effects of imatinib discussed elsewhere. TG100-115 In short, the aggressiveness of the treatment t be balanced against the risk of disease progression. Dose reduction of less than 300 mg per day are not suitable for the restoration of the blood-forming ESE normal help, but it can mix the emergence of leuk Imatinibresistant clones. To manage to 3-4 myelosuppression grade G-CSF, is an option. The temporary interruption of the treatment, it is preferable to reduce the dose of the chronic phase.
Patients with advanced stage of the disease is unclear whether. VX-745 The best option to continue the treatment with imatinib in the face of severe myelosuppression and manage complications or aggressive, as with patients in chronic phase Ver approach in this situation Ffentlicht was not terminated in the treatment or reduce the dose on the basis of thrombocytopenia, but fa To support such patients platelet transfusions. If the bleeding can not be clinically significant imatinib should be stopped immediately until the bleeding is under control EEA. In addition, the cell density in the bone marrow for Spitzenbetr Ge Leuk be Studied chemistry and if the absolute neutrophil count falls below 500 mm3. Patients whose bone marrow is hyperzellul Acids with blasts or gr He is over 30, should continue imatinib.
If the bone marrow hypozellul Ren and the ANC is less than 500 mm 3 for 2 4 weeks Dose reduction of imatinib, temporary treatment interruption, or the use of myeloid growth factors Approx Hr 2 weeks w While the are usually options. Toxicity th Non-h Dermatological side effects, the h Most frequent h Dermatological Phase II and III clinical trials were nausea, Muskelkr Cramps, fl uid retention, diarrhea, musculoskeletal pain, fatigue and rash. Few patients had non-h Hematological toxicity t Grade 3 April. The incidence of side effects was different specifications c depending on the stage of CML. For example, the retention is fl uid and vomiting h More common in advanced disease, w While symptoms Skeletal muscle and my weight gain were h More frequently in the chronic phase.
At the same time found more monitoring additionally some USEFUL not-h Hematological toxicity t that anf Not accessible reports. Gastrointestinal side effects are nausea and vomiting sometimes toxicity Th h Frequently observed with imatinib. These side effects are usually mild and dose related. You can k Can be avoided in most patients when imatinib with food that is not occupied ver Alters the pharmacokinetics of drugs. Patients with a history of Esophagitis or hiatus hernia is recommended that the drug should be taken at least 2 hours before bedtime and 800 mg as 400 mg two separate meals are taken to local irritant to avoid feeder Hre and gastric mucosa. If nausea is not adequately controlled Controlled by the administration of antiemetics such simple Ma took K Can better provide relief to the patient. Diarrhea is another relatively h Frequently dose- Ngig side effect of imatinib. It is possible to change the diarrhea is cau